Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It se… Read more
Neuraxis, Inc. (NRXS) - Total Liabilities
Latest total liabilities as of September 2025: $3.49 Million USD
Based on the latest financial reports, Neuraxis, Inc. (NRXS) has total liabilities worth $3.49 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neuraxis, Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Neuraxis, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Neuraxis, Inc. Competitors by Total Liabilities
The table below lists competitors of Neuraxis, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LSL Pharma Group Inc.
V:LSL
|
Canada | CA$34.81 Million |
|
Numulae Gestion de Servicios SOCIMI SA
MC:YNUM
|
Spain | €21.51 Million |
|
Heubach Colorants India Limited
NSE:HEUBACHIND
|
India | ₹1.91 Billion |
|
Acorn Energy, Inc. Common Stock
OTCQB:ACFN
|
USA | $5.20 Million |
|
Camus Engineering & Construction Inc
KO:013700
|
Korea | ₩166.38 Billion |
|
Hep Tech Co Ltd
TWO:3609
|
Taiwan | NT$627.55 Million |
|
Company K Partners Limited
KQ:307930
|
Korea | ₩4.09 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Neuraxis, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuraxis, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuraxis, Inc. (2020–2024)
The table below shows the annual total liabilities of Neuraxis, Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.69 Million | +40.63% |
| 2023-12-31 | $1.91 Million | -72.89% |
| 2022-12-31 | $7.05 Million | +344.74% |
| 2021-12-31 | $1.59 Million | +38.43% |
| 2020-12-31 | $1.15 Million | -- |